Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. addition

ADDITION

Arthritis Differential DIagnostic validaTION

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 ADDITION project word cloud

Explore the words cloud of the ADDITION project. It provides you a very rough idea of what is the project "ADDITION" about.

probabilities    line    pcr    cohort    functional    acr    efficacy    earlier    incidence    subclass    expenses    joints    inflammation    ineffective    synovial    validated    clinicians    progression    genes    ing    feasibility    techniques    infrastructure    ea    eular2010    unsatisfactory    computing    patients    group    1000    280m    involve    tool    annual    predict    strategies    cloud    criterion    complemented    accuracy    trancriptomic    treatments    limited    500    suffering    diseases    huge    mistake    diagnostic    describes    therapeutic    spondylarthropaties    collection    diagnosed    provides    biopsy    inappropriate    procedure    solution    marked    impacts    turnover    140m    consists    market    leads    newly    vs    few    ra    useless    unjustified    signature    patient    transportation    ua    treatment    logistics    economic    adequacy    rheumatoid    distinction    40    prospective    90    health    clinical    differential    central    arthritis    undifferentiated    socio    clinically    web    mtx    ce    methotrexate    rheumakit    larger    serious    validate    seronegative    osteoarthritis    lab    first    kit    2014   

Project "ADDITION" data sheet

The following table provides information about the project.

Coordinator		 DNALYTICS 

Organization address
address: CHEMIN DU CYCLOTRON 6
city: OTTIGNIES LOUVAIN LA NEUVE
postcode: 1348
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Belgium [BE]
 Project website http://www.dnalytics.com. The RheumaKit online platform
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-04-01   to  2015-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    DNALYTICS BE (OTTIGNIES LOUVAIN LA NEUVE) coordinator 50˙000.00

Map

 Project objective

Arthritis, a group of diseases involving inflammation of joints with huge health and socio-economic impacts. Early Arthritis (EA) describes newly diagnosed arthritis (incidence 2/1000). An improved arthritis management requires to enhance the EA differential diagnostic efficacy and the adequacy of the therapeutic strategies. The earlier arthritis is addressed, the more likely its progression will be limited. A mistake in differential diagnostic leads to inappropriate treatments, resulting in useless expenses and serious side effects, unjustified. Current diagnostic techniques are unsatisfactory and the most used first line treatment, Methotrexate (MTX), is ineffective in about 40% of the patients. RheumaKit is a solution for clinicians for the early differential diagnostic of patients suffering from undifferentiated arthritis (UA, a subclass of EA). RheumaKit is based on a trancriptomic signature of about 100 genes complemented by 3 clinical factors. It provides a 90% accuracy for the Rheumatoid Arthritis (RA) vs non-RA distinction, far above the ACR/EULAR2010 criterion on the same patients. It also provides probabilities for Osteoarthritis and Seronegative Spondylarthropaties. The solution consists of a synovial biopsy collection and transportation kit (CE-marked May 2014), a central lab PCR procedure, and a web application computing the effective diagnostic on a cloud-computing infrastructure. Functional, technical, logistics aspects of RheumaKit have been validated. ADDITION aims at clinically validate on a larger patient cohort the existing RheumaKit signature for the differential diagnostic of most EA patients and validate the use of the existing RheumaKit signature as a tool to predict MTX response. ADDITION phase 2 will involve a prospective study on 500 to 1000 EA patients. The main phase 1 objectives are a feasibility study of the clinical and market aspects of ADDITION. The expected annual turnover is above 140M€-280M€ in EU within a few years.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ADDITION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ADDITION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

AutoCRAT (2020)

Automated Cellular Robot-Assisted Technologies for translation of discovery-led research in Osteoarthritis

Read More